Chapter Twenty-Seven - New Chemical Entities Entering Phase III Trials in 2012

• Autores: Gregory T. Notte
• Localización: Annual reports in medicinal chemistry, ISSN 0065-7743, Vol 48, 2013, págs. 451-469
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Abstract This year’s JOURter of New Chemical Entities Entering Phase III Trials provides an overview of novel synthetic organic molecules entering Phase III clinical trials in the United States. From the 1426 Phase III trials registered at ClinicalTrials.gov in 2012 classified as having a “drug intervention,” 39 compounds met the selection criteria for inclusion (e.g., synthetic in origin, first time reaching Phase III for any indication, structure available). This summary provides a quick reference for those wishing to track the progress of drug candidates as they move closer to approval and complements the information provided in JOURter 28. Beginning this year, statistics regarding the current status of the molecules included in previous year’s JOURters will be provided. Notably, this year’s JOURter includes Ponatinib, which received fast track status and was approved based on Phase II results prior to the conclusion of Phase III trials.